Developed and developing countries

12
Prevalence and Impacts on Developed and Developing Countries

Transcript of Developed and developing countries

Page 1: Developed and developing countries

Prevalence and Impacts on Developed

and Developing Countries

Page 2: Developed and developing countries

Methicillin-resistant S aureus Infection Rates

Produced by CDDEP, found at: http://www.cddep.org/tool/mrsa_infection_rates_country#sthash.4eSoOCcP.zR0cdm2A.dpbs

Page 3: Developed and developing countries

Much greater than a third world problem

Prevalence of certain antibiotic resistant strains (notably MRSA) a growing problem in many developed countries1 – not just in developing countries

USA and the UK were ranked among the countries with the highest prevalence of MRSA infection rates

Spread of resistance is facilitated by interspecies gene transmission, poor sanitation and hygiene in communities and hospitals, and the increasing frequency of global, travel, trade, and disease transmission1

Page 4: Developed and developing countries

Number of cases showing a resistance causing genetic

element by country

Produced by the IMF, found at: http://www.imf.org/external/pubs/ft/fandd/2014/12/jonas.htm

Page 5: Developed and developing countries

A Global ProblemIn high-income countries, continued high rates

of antibiotic use in hospitals, the community, and agriculture have contributed to sustained resistant strains, forcing a shift to more expensive and more broad-spectrum antibiotics1

In low-income and middle-income countries (LMICs), antibiotic use is increasing with rising incomes, high rates of hospitalization, and high prevalence of hospital infections1

Page 6: Developed and developing countries

MortalityAn estimated 25 000 people die every year in

Europe from antibiotic-resistant bacteria2

A report conservatively estimated that at least 2 million illnesses and 23 000 deaths a year in the USA were caused by antibiotic resistance3

Few reliable estimates are available for lower and middle income countries, but the higher burden of infectious disease and restricted access to new antibiotics suggest a far higher burden than in high-income countries1

Page 7: Developed and developing countries

Healthcare Associated InfectionsIncidence of infections acquired in intensive care

units in developing countries was three times the rate in the USA4

Health-care associated infections in neonatal intensive care units in some developing countries are up to nine times more common than in the USA4

In lower and middle income countries the burden of resistance seems only likely to increase with the rate of health-care associated infections4

Page 8: Developed and developing countries

Increased Cost of Treatment

A global need for more expensive antibiotics to treat resistant infections has been driving up treatment costs in both developing and developed countries1

In lower and middle income countries, the ability to pay for second-line drugs is limited when cheaper, first line drugs are ineffective1

Leads to much worse health outcomes, especially in neonates1

Page 9: Developed and developing countries

Some ImprovementsResistance to MRSA in some parts of Western

Europe has been decreasing5 In high-income countries, it is being tackled with

a combination of new antibiotics and better hospital infection control5

Many of the lower and middle income countries have been unable to implement many of these policies, and have not seen the same improvements5

See the following map5

Page 10: Developed and developing countries
Page 11: Developed and developing countries
Page 12: Developed and developing countries

References1. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al.

Antibiotic resistance—the need for global solutions. The Lancet infectious diseases. 2013;13(12):1057-1098

2. ECDC/EMEA Technical Report. The bacterial challenge: time to react http://www.ecdc.europa.eu/en/publications/Publications/0909_TER_The_Bacterial_Challenge_Time_to_React.pdf (Sept 2009) 

3. US Centers for Disease Control and Prevention Antibiotic resistance threats in the United States, 2013 http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf (April 2013) 

4. Allegranzi B, Nejad SB, Combescure C, Graafmans W, Attar H, Donaldson L, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. The Lancet. 2011;377(9761):228-241.

5. Hede K. Antibiotic resistance: an infectious arms race. Nature. 2014;509(7498):S2-S3.